This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): CI-1042
Onyx-015 is an attenuated synthetic adenovirus that selectively replicates in p53-deficient cancer cells. A precursor to gene therapy, Onyx-015 theoretically kills only cancer cells lacking the tumor suppressor p53. In vitro and in vivo preclinical support for the advancement of this construct into clinical trials for multiple solid tumor types is extensive and compelling.
Onyx cancelled clinical trial development of Onyx-015 in January 2003.
In September 1999, Onyx partnered with Warner-Lambert (a division of Pfizer) to develop Onyx-015. Warner-Lamberts role was reduced in August 2001, and discontinued in September 2002.
In January 2001, Xoma agreed to manufacture Onyx-015 for Onyx. That agreement was suspended in January 2003.
Onyx and Amgen
In August 2013, Amgen and Onyx announced that their Boards of Directors have unanimously approved a transaction under which Amgen will acquire all of the outstanding shares of Onyx for $125 per share in cash. The purchase price is $10.4 billion, or $9.7 billion net of estimated Onyx cash. Amgen intends to effect the transaction through a tender offer.
In October 2013, Amgen announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Onyx for $125 per share in cash. As announced on August 25, the purchase price is $9.7 billion net of estimated Onyx cash. The tender offer...See full deal structure in Biomedtracker
Pink Sheet Weekly Trademark Review July 19, 2016
Pink Sheet Weekly Trademark Review Nov. 4, 2014
Additional information available to subscribers only: